Allan Larcena, MD
Internal Medicine · Slidell, LANPI 1275579724
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 793 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 40 manufacturers reported payments, led by AstraZeneca at 27.9% of the total. Reporting peaked in 2021 at $2,991 and has fallen 54.4% since, to $1,363 in 2025. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 793 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$3K
- AbbVie$2K
- Boehringer Ingelheim$865
- Lilly USA, LLC$857
- Amarin Pharma, Inc.$727
- plus $4K from 34 others
Across 33 payments — averaging $4126.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Currax Pharmaceuticals LLC$93K
- GSK$23K
- Modernatx, Inc.$21K
What the payments were for
- Food & beverage$15,40398%
- Education$2221%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,684 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 343 | $426,981 |
| JardianceEmpagliflozin | 266 | $221,040 |
| OzempicSemaglutide | 175 | $187,270 |
| FarxigaDapagliflozin Propanediol | 199 | $139,773 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $89,463 |
| VascepaIcosapent Ethyl | 146 | $76,953 |
| EliquisApixaban | 78 | $56,970 |
| TradjentaLinagliptin | 56 | $51,508 |
| JanuviaSitagliptin Phosphate | 49 | $41,000 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $39,120 |
| TrulicityDulaglutide | 27 | $32,617 |
| LinzessLinaclotide | 47 | $32,104 |
| MyrbetriqMirabegron | 49 | $23,448 |
| XareltoRivaroxaban | 25 | $15,313 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $14,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $857 | $459,599370 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $865 | $280,310334 claims |
| Novo NordiskOzempic | $587 | $187,270175 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $4,381 | $182,030272 claims |
| GSKTrelegy Ellipta | $3,273 | $89,463135 claims |
| PfizerEliquis | $434 | $56,97078 claims |
| MerckJanuvia | $21 | $41,00049 claims |
| AbbVieLinzess | $1,565 | $32,10447 claims |
| Astellas Pharma US IncMyrbetriq | $267 | $23,44849 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl | $79 | $16,15782 claims |
| Johnson & JohnsonXarelto | $56 | $15,31325 claims |
| NovartisEntresto | $340 | $13,25120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Slidell
- Abhishek GargSlidell$15K
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Bruce SamuelsCovington$200K
- Amanda FontenotMarrero$142K
- John SchwabBaton Rouge$122K
- Daniel EnglertNew Orleans$74K
- Everett BrownGretna$71K
- Rajan KhannaShreveport$54K
- Samuel StaggEunice$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.